Coherus Oncology Announces Preliminary Underwritten Public Offering of Common Stock
CHRS has more than doubled off its 52-week low of $0.71.
Summary
Coherus Oncology has filed a preliminary prospectus supplement for a new underwritten public offering of common stock, with the offering size and pricing yet to be determined.
Key Events · Financing and Capital Events · CHRS
-
New Underwritten Public Offering
Coherus Oncology, Inc. has filed a preliminary prospectus supplement for an underwritten public offering of its common stock. The offering size and pricing details are not yet finalized.
-
Follows Recent Capital Raise
This new offering follows a previous At-The-Market (ATM) offering of up to $64.9 million initiated on January 23, 2026, indicating a continued need for capital.
-
Use of Proceeds
The company intends to use the net proceeds to support the commercialization of LOQTORZI, continue clinical development of product candidates, and for general corporate purposes.
Analysis · CHRS · Life Sciences
Coherus Oncology, a life sciences company, has filed a preliminary prospectus supplement for a new underwritten public offering of common stock. While the specific dollar amount and pricing of the offering are not yet disclosed, this filing indicates the company's intent to raise additional capital. This follows a recent At-The-Market (ATM) offering of up to $64.9 million initiated on January 23, 2026, and preliminary Q4 and full-year 2025 financial results announced on January 13, 2026, which highlighted a cash position of approximately $172.1 million as of December 31, 2025, expected to fund operations through the end of 2026. This new offering, if completed, would provide further capital to support the commercialization of LOQTORZI, advance clinical development of product candidates, and for general corporate purposes, potentially extending the company's financial runway. However, any equity offering will result in dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 29.6% of the 1592 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CHRS was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243M. The 52-week trading range was $0.71 to $2.62. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.